在治疗周围神经损伤时使用基托基生物聚合物的前景
Meng Zhang1,2, Heng An3, Fengshi Zhang1,2
1Department of Orthopedics and Trauma, Peking University People's Hospital, Beijing 100044, China.
International journal of molecular sciences
|August 26, 2023
概括
基托基生物聚合物显示出对外围神经再生的承诺,提供更好的生物相容性和细胞生长刺激. 这些先进的生物材料可以为神经损伤提供更好的治疗方法.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 神经科学是一个神经科学.
背景情况:
- 周围神经受伤很普遍,目前的治疗方法效果有限.
- 基托基生物聚合物正在成为一个有前途的治疗途径.
- 这些生物聚合物具有独特的特性,有利于神经修复.
研究的目的:
- 审查基托基生物聚合物的最新进展,用于外围神经再生.
- 突出这些生物材料在改善神经修复结果方面的潜力.
- 探索它们在药物输送系统中的应用,以增强神经生长.
主要方法:
- 关于基托基生物聚合物在外围神经再生中的研究的综合文献综述.
- 对神经修复 (生物相容性,生物降解性,细胞增殖) 相关的基托桑性质的分析.
- 评估基托桑在治疗剂释放的药物输送系统中的作用.
主要成果:
- 酸盐生物聚合物显示出出色的生物相容性和生物降解性.
- 它们有效地刺激细胞增殖,这对神经再生至关重要.
- 素可以被设计为可控的药物输送,以支持神经细胞生长.
结论:
- 基托基生物聚合物代表了对外围神经再生的新有效策略.
- 它们的独特特性有助于神经缺陷的修复和功能恢复.
- 进一步的研究有潜力开发创新的治疗方法,改善患者的治疗结果.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Traumatic Brain Injury l: Introduction
DefinitionTraumatic brain injury, or TBI, is a disturbance of normal brain function induced by an external mechanical force, such as a direct blow to the head or a penetrating injury. It can affect both brain structure and function, producing a wide range of clinical outcomes. TBI is a heterogeneous condition, meaning its effects may differ based on the type, location, and severity of the injury.Basis of ClassificationTBI is classified based on severity, injury mechanism, or pathophysiology. In...


